atibiotic study guide Flashcards

1
Q

Drugs that weaken cell walls

A
 PCNs
 Cephalosporins
 Carbapenems
 Fosfomycin
 Vancomycin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Bacteriostatic Inhibitors of Protein Synthesis

A

 Macrolides
 Tetracyclines
 Ketolides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Competitive Antimetabolite in the Synthesis of Folic Acid

A

Sulfonamides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CA-MRSA

A

Sulfonamides (less effective secondary to resistance):

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sulfonamides (less effective secondary to resistance):

A

PCN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Staph (Skin, bone, joint)

A

Penicillinase Resistant Penicillins (PRPs):

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Strep and Group A Strep (GAS)

A

Natural and broad-specturm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Β-Lactamase Inhibiting Compounds (BLIC):

A

respiratory, S. pneumoniae, GAS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

staph and strep (Gr + activity)

A

Cephalosporins 1st and 4th generations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cephalsporin 2nd gen

A

Moderate Gr+ activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cephlasporin 3rd

A

more Gram - coverage than Gram + coverage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Some Staph, indicated for CA-MRSA

A

Tetracyclines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Staph, poor activity S. pneumonaie

A

Fluoroquinolones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

variable activity against Gram + Strep and Staph; some Gram + bacilli (Gut)

A

Macrolides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

UTI (growing resistance TMP-SMX), less respiratory coverage secondary to
resistance. Special use Pneumocystis carinii

A

Sulfonamides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Gram – cocci and some Gram –

bacilli (UTI, although growing resistance)

A

Penicillins Natural

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

: Gram – bacilli, pseudomonas BLIC: Gram + and

Gram –

A

Extended spectrum (Ticarcillin, Piperacillin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

aerobic Gr- (GI/GU); not effective against anaerobes

A

Fluoroquinolones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Some Gram – (Gut). Campylobacter, Legionella Cover Weird Intracellular (atypical):
Chlamydia, Ureaplasma, Mycoplasma

A

Macrolides

20
Q

Gram - ; limited by side effects Cover weird Intracellular (atypical): Chlamydia,
Ureaplasma, Mycoplasm

A

Tetracyclines

21
Q

. Decreased Permeability

A

(e.g., Pseudomonas)

22
Q

Antibiotic Efflux Pump

A

• (e.g., S. pneumoniae vs. quinolones, macrolides)

23
Q

Drug Inactivation

A

(e.g., -lactamase from H. influenzae, Staph, E. coli, Klebsiella)

24
Q

Altered Target Site

A

(e.g., S.pneumoniae (altered PBPs), S. pneumonia vs macrolides (ribosomal methylase), S.
pneumoniae vs quinolones (GyrA, Topo4))

25
Q

Gram +

A

(SSE) Strep, Staph, Enterococcus – Skin, soft tissue, respiratory

26
Q

Gram -

A

H. flu, Neisseria, Moraxella – Respiratory, Meningtitis, GU
(EKP): E-coli, Klebsiella, Proteus – GU
(ESP) Enterobacter, Serratia, Providencia – GI
Salmonella, Shigella – GI

27
Q

Atypicals

A

Chlamydia, Mycoplasm, Legionella – Respiratory, GU

28
Q

Pseudomonas

A

—Respiratory, other

29
Q

Bacteroides

A

GI, Respiratory

30
Q

SSE infection site

A

Skin, soft tissue
Respiratory tract
GI/GU

31
Q

SSE Treatment

A

Gr + Action: PCNs, Carbapenems, macrolides,
clindamycin, tetracyclines, fluoroquinolones,
cephalosporins

PCNs* Aminoglycosides*, glycopeptides

32
Q

HNM Infection site

A

AOM, sinusitis, bronchitis
Meningitis
GU
AOM, sinusitis, bronchitis

33
Q

HNM treatment

A

Gr- action: Macrolides, carbapenems,
ketolides, fluoroquinolones, 3/4
cephalosporins,

34
Q

EKP infection site

A

UTI, GI

35
Q

ESP Infection Site

A

GI

36
Q

Salmonella, Shingella Infection site

A

GI

37
Q

EKP treatment

A

Gr- action:Carbapenems, aminoglycoside
fluoroquinolones, 2/3/4 cephalosporins,
TMP-SMX

38
Q

ESP Treatment

A

Stronger Gr- action: Carbapenems, 3/4
cephalosporins, fluoroquinolones,
aminoglycosides

39
Q

Salmonella, Schigella Treatment

A

TMP-SMS, PCN (Shigella

40
Q

Pseudomonals Infection site

A

Pneumonia, various

41
Q

Bacterioides infection site

A

GI, Aspiration Pneumonia

42
Q

Bacteroids treatment

A

Carbapenems, Clindamycin, Tetracycline

43
Q

Pneumona, various treatment

A

Aminoglycoside, βlactam,quinolone,3cef

44
Q

Immediate (Most emergent: urticare, angioedema, anaphylaxis)

A

Type 1

45
Q

Cytotoxic (Activation of the complement cascade: PCNS and Sulfa most common)

A

Type 2

46
Q

Delayed Immune Complex Reactions (Complement fixation induced and lodged in small
blood vessels skin, kidneys, joints: Serum Sickness)

A

Type 3

47
Q

Cell Mediated Reaction (topical applications; hypersensitivity)

A

Type 4